NASDAQ:PRAX 16 October 2025 - 14 January 2026

Shares of Praxis Precision Medicines rose about 8% to $303.23 by mid-afternoon Wednesday after the company named epilepsy specialist Dr. Orrin Devinsky as head of clinical strategy. Investors are watching two FDA drug applications set for mid-February. Praxis recently raised $575 million in a public offering. The broader biotech sector outperformed the market, while major indexes fell.

Praxis Precision Medicines shares rose about 6% midday Wednesday after the company priced a $575 million stock offering at $260 per share, below Tuesday’s $272.90 close. The stock last traded near $289.50. Praxis reported about $925 million in cash and marketable securities at year-end. The offering is expected to close Jan. 8.

Praxis Precision Medicines shares surged 30.5% to close at $247.99 on December 5, hitting a new 52-week high after positive epilepsy trial results and a favorable FDA pre-NDA meeting. The company’s market cap reached about $6.2 billion. PRAX stock has gained over 500% in three years but remains down 72% over five years. Wall Street sentiment is mostly positive, though some skepticism remains.

Praxis Precision Medicines shares traded around $189.97 early December 5 after surging on positive FDA feedback for its essential tremor drug and new data in rare epilepsies. The stock swung between $180.25 and $305.55 intraday, with a market cap near $1.1 billion. PRAX has gained over 1,700% in 12 months, but remains volatile amid short-seller pressure and ongoing losses.

Praxis Precision Medicines shares soared 183% to $162.71 on Thursday after its drug ulixacaltamide met all key goals in a Phase 3 trial for essential tremor. The results showed significant improvement in patient function and no serious side effects. The company plans to seek FDA approval by early 2026 and launched a public stock offering to fund commercialization.